Mentioned in

References in periodicals archive

Overall, the investigators found 19,017 patients who were prescribed both triptans and an SSRI or SNRI.

Serotonin syndrome risk with triptans and antidepressants very low

For women with breast cancer who are taking an aromatase inhibitor, and who are also experiencing mood changes with their hot flashes, we often choose a trial of a low-dose antidepressant, either an SSRI or SNRI. One drug is approved by the US Food and Drug Administration (FDA) for the treatment of hot flashes (but not for mood disorder).

Managing menopausal vasomotor and genitourinary symptoms after breast cancer: Two cases on selecting safe and useful treatments for survivors of breast cancer experiencing distressing quality-of-life symptoms of menopause

Food and Drug Administration issued an advisory warning on the risk of serotonin syndrome with concomitant use of triptans and SSRI or SNRI antidepressants, Yulia Orlova, M.D., Ph.D., from Brigham and Women's Hospital in Boston, and colleagues used electronic health record data to examine the risk of serotonin syndrome.

Low Risk of Serotonin Syndrome for Triptans + SSRI/SNRI; Researchers question FDA advisory warning on risk of concomitant use

A 2015 meta-analysis that examined nine randomized controlled trials of SSRIs and serotonin and norepinephrine reuptake inhibitors (SNRIs) for pediatric anxiety disorders concluded that these agents provided a benefit of modest effect size.

Anxiety disorders: Psychopharmacologic treatment

The spectral distortions for the 25 words are shown in Figure 8 for an SNRI of 3 dB.

Comparative Study between the Discrete-Frequency Kalman Filtering and the Discrete-Time Kalman Filtering with Application in Noise Reduction in Speech Signals

In another study it was seen that adding L-Methylfolate to selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) when starting pharmacotherapy leads to greater reduction of depressive symptoms in a shorter time compared with SSRI or SNRI monotherapy8.According to the study the efficacy of L-Methylfolate and SSRI was 18.5% as compared to 7.04% efficacy of SSRI or SNRI monotherapy9 showing a difference in response of 11.5% Papakostas et all showed that adjunctive L-methylfolate at 15mg/day showed significantly greater efficacy compared with continued SSRI therapy plus placebo on both primary outcome measures (response rate and degree of change in depression symptom score) and two secondary outcome measures of symptom severity10.

THERAPEUTIC EFFICACY OF COMBINATION THERAPY OF L-METHYLFOLATE AND ESCITALOPRAM IN DEPRESSION

First-line medication is a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI) due to the better tolerability and lower adverse effect profile of these classes compared with the tricyclic antidepressants or monoamine oxidase inhibitors.

Ensuring prompt recognition and treatment of panic disorder

The medication that most effectively kept patients from returning to the hospital was not a selective serotonin reuptake inhibitor (SSRI), a serotonin nor-epinephrine reuptake inhibitor (SNRI), or an atypical antipsychotic.

RETHINKING LITHIUM: Drug keeps patients with unipolar depression out of the hospital

SSRI: Serotonin reuptake inhibitors, SNRI: Serotonin noradrenaline reuptake inhibitors, TCA: Tricyclic antidepressants, AED: Antiepileptic drugs, GABA: Gamma amino butyric acid

Age- and gender-related differences in drug utilization patterns among patients in neurology ward of a tertiary care hospital

The increased risk was associated with all of the most frequently used antidepressant groups, which were selective serotonin reuptake inhibitors (SSRI drugs), mirtazapine and selective noradrenaline reuptake inhibitors (SNRI drugs).

Antidepressant use increases hip fracture risk among elderly